Using the bacterium E. coli, researchers from the University's Faculty of Engineering showed it was possible to vastly increase the efficiency of the cells producing specifically modified proteins, as well as improve its performance and stability. The modification is present in over two-thirds of human therapeutic drugs on the market and involves the addition of specific sugar groups to the protein backbone, a process termed glycosylation.
Drugs based on proteins are increasingly important in modern medicine to tackle health problems including diabetes, cancer and arthritis.
Although simple proteins are traditionally made in microbial cells, these types of complex drugs are made using animal cells because they can make human-type glycosylations that will control its efficacy and stability in the body, and avoid immunogenic reactions in patients.
Using bacteria to make proteins for use as medicines could be a more cost effective alternative, since using animal cells is expensive. However, the efficiency of glycoprotein production in bacterial cells is still very poor, with yields often several thousand times lower than in animal cells.
Now, researchers in the Department of Chemical and Biological Engineering at the University of Sheffield, with collaboration from the University of Colorado, are using a technique called inverse metabolic engineering, that allows them to screen cells to identify strains that are likely to be the most efficient glycoprotein producers. Using this method, the team were able to produce seven times as much of the protein in laboratory tests.
The team then used mass spectrometry to characterise and accurately quantify the proteins being produced by the bacteria. This allowed them to pinpoint modifications that will enable them, ultimately, to improve the performance of the drug.
Professor Phil Wright, who led the research, said: "We believe that this technique will pave the way for pharmacologists to get the same protein yield from bacteria cells as they could from animal cells and also enable them to produce drugs from bacteria that have vastly improved focus and accuracy."
The team also tested the technique on antibody fragments with positive results, showing that their approach could work in different proteins.